MTOR and neoplasm: The activation of the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway eventually leads to activation of mTORC1/2, leading to cell survival, proliferation, and neoplasia [39].